Statistics from Altmetric.com
Venous thromboembolism (VTE) is a common and costly disorder. Limitations of current treatment options include the need for a multidrug regimen (parenteral and oral), labour-intensive monitoring and frequent adverse events. Rivaroxaban is an investigational, oral, direct factor Xa inhibitor. It provides effective VTE prevention in hip and knee replacement1,–,4 and stroke prevention in atrial fibrillation.5 This article reports the results of two rivaroxaban trials: treatment of acute deep vein thrombosis (DVT) and long-term treatment of DVT or pulmonary embolism (PE) after initial therapy.
The acute DVT study is a randomised, open label non-inferiority trial comparing rivaroxaban with standard therapy for acute, symptomatic, proximal DVT. Participants received rivaroxaban 15 mg twice daily for 3 weeks, then 20 mg daily for 3, 6 or 12 months; alternatively, they received enoxaparin 1.0 mg/kg twice daily bridging to a vitamin K antagonist (target …
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.